Cargando…
Tofacitinib in Refractory Scleritis: A Case Series
Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitin...
Autores principales: | Dey, Suvankar, Sarkar, Rajdeep, Pradhan, Amrita, Padhan, Prasanta, Maikap, Debashis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Mediterranean Journal of Rheumatology (MJR)
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628867/ https://www.ncbi.nlm.nih.gov/pubmed/37941862 http://dx.doi.org/10.31138/mjr.20230828.ti |
Ejemplares similares
-
Successful Use of Tofacitinib in Refractory Takayasu Arteritis: A Case Series
por: MV, Prakashini, et al.
Publicado: (2023) -
Successful Use of Tofacitinib in Scleroderma Arthropathy
por: MV, Prakashini, et al.
Publicado: (2023) -
Tofacitinib for refractory uveitis and scleritis
por: Paley, Michael A., et al.
Publicado: (2018) -
Trigeminal Neuralgia as an Initial Presentation of Systemic Autoimmune Diseases: A Case Series
por: Maikap, Debashis, et al.
Publicado: (2022) -
Unusual Cause of Vision Loss in a Case of Lupus
por: Padhan, Prasanta, et al.
Publicado: (2022)